Vanta Bioscience Balance Sheet Annual

Trade

BSE: 540729 | NSE: - | ISIN: INE695X01011 | Sector: Biotechnology & Drugs

47.32 +2.16 (4.78%)Updated : 26 Nov 2024

Interim Data

Annual Data

Fiscal Period	2024	2023	2022	2021
Period End Date	Mar 24	Mar 23	Mar 22	Mar 21
Cash	0.16	0.10	0.22	2.65
Cashand Short Term Investments	0.16	0.10	0.22	2.65
Accounts Receivable- Trade Net	3.14	1.96	1.13	2.03
Total Receivables Net	8.92	7.34	6.32	6.02
Total Inventory	7.52	7.16	7.24	9.76
Other Current Assets Total	0.56	0.65	0.72	0.00
Total Current Assets	17.16	15.24	14.50	19.94
Property/ Plant/ Equipment Total- Net	28.41	33.23	37.32	34.86
Intangibles Net	25.75	24.00	21.59	13.87
Other Long Term Assets Total	14.08	12.24	8.00	0.45
Total Assets	85.40	84.71	81.40	69.63
Accounts Payable	5.57	4.22	2.46	0.47
Current Portof LT Debt/ Capital Leases	12.15	6.36	7.87	8.13
Other Currentliabilities Total	5.16	3.43	3.95	5.39
Total Current Liabilities	22.88	17.75	14.28	14.84
Long Term Debt	48.80	47.07	37.00	27.84
Total Long Term Debt	48.80	47.07	37.00	27.84
Total Debt	60.95	57.16	44.87	35.97
Deferred Income Tax	0.75	0.97	0.78	0.72
Minority Interest	-2.23	1.41	5.34	2.31
Other Liabilities Total	0.00	0.00	0.00	0.00
Total Liabilities	70.20	67.19	57.40	45.71
Common Stock Total	6.31	6.31	6.31	6.31
Retained Earnings( Accumulated Deficit)	8.89	11.20	17.70	2.39
Total Equity	15.20	17.51	24.01	23.92
Total Liabilities Shareholders' Equity	85.40	84.71	81.40	69.63
Total Common Shares Outstanding	0.63	0.63	0.63	0.63
Tangible Book Valueper Share Common Eq	-16.71	-10.27	3.84	15.93
Notes Payable/ Short Term Debt	-	3.73	0.00	0.00
Short Term Investments	-	-	-	0.00
Prepaid Expenses	-	-	-	1.50
Property/ Plant/ Equipment Total- Gross	-	-	-	19.24
Accumulated Depreciation Total	-	-	-	-3.72
Note Receivable- Long Term	-	-	-	0.52
Accrued Expenses	-	-	-	0.86
Additional Paid- In Capital	-	-	-	15.21